Rapt Therapeutics (RAPT) announced that the U.S. FDA has cleared Rapt’s Investigational New Drug Application to proceed to a Phase 2b clinical trial of RPT904 for the treatment of patients with food allergy. The planned Phase 2b trial in food allergy is a randomized double-blind placebo-controlled study designed to evaluate the safety and efficacy of RPT904 dosed every 8 weeks and every 12 weeks.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Leerink upgrades Rapt Therapeutics on food allergy opportunity for RPT904
- Rapt Therapeutics upgraded to Outperform from Market Perform at Leerink
- Rapt Therapeutics price target raised to $9 from $8 at UBS
- Promising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating
- Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo